Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024

REHOVOT, Israel, and HOBOKEN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the second quarter and first half ended June 30, 2024, prior to the open of the U.S. financial markets on Wednesday, August 14, 2024.

Kamada management will host an investment community conference call on Wednesday, August 14 at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 1-877-407-0792 (from within the U.S.) or 1-809-406-247 (from Israel) or 1-201-689-8263 (International) using conference ID 13747542. The call will also be webcast live on the Internet at: https://viavid.webcasts.com/starthere.jsp?ei=1678713&tp_key=b3f21d48c3

The call will also be archived for 90 days on the Company’s website at www.kamada.com.

About Kamada

Kamada Ltd. (the “Company”) is a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, focused on diseases of limited treatment alternatives. The Company is also advancing an innovative development pipeline targeting areas of significant unmet medical need. The Company’s strategy is focused on driving profitable growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical fields. The Company’s commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products: KEDRAB®, CYTOGAM®, WINRHO SDF®, VARIZIG®, HEPAGAM B® and GLASSIA®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India Australia and other countries in Latin America, Europe, the Middle East, and Asia. The Company leverages its expertise and presence in the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers. During recent years the Company added eleven biosimilar products to its Israeli distribution portfolio, which, subject to European Medicines Agency (EMA) and the Israeli Ministry of Health approvals, are expected to be launched in Israel through 2028. The Company owns an FDA licensed plasma collection center in Beaumont, Texas, which currently specializes in the collection of hyper-immune plasma used in the manufacture of KAMRHO (D), KAMRAB and KEDRAB. In addition to the Company’s commercial operation, it invests in research and development of new product candidates. The Company’s leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares.

CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com

Brian Ritchie
LifeSci Advisors, LLC
(212) 915-2578
britchie@LifeSciAdvisors.com

Staff

Recent Posts

EliseAI, World Leader in AI-Enabled Solutions for Housing, Raises $75 Million Series D Round Valuing Company in Excess of $1 Billion

Latest Round of Financing, Led by Sapphire Ventures, Establishes EliseAI’s Unicorn StatusNEW YORK--(BUSINESS WIRE)--EliseAI, the…

1 hour ago

EliseAI, World Leader in AI-Enabled Solutions for Housing, Raises $75 Million Series D Round Valuing Company in Excess of $1 Billion

Latest Round of Financing, Led by Sapphire Ventures, Establishes EliseAI’s Unicorn StatusNEW YORK--(BUSINESS WIRE)--EliseAI, the…

1 hour ago

Ludwig Announces Substantial Corporate Initiatives

Revealia™, the world’s most convenient cancer screening test, to launch in 2024 SPARKS, NV /…

1 hour ago

‘Top Workplace’ Gets Even Better Place to Work: US Med-Equip Expands with New National Headquarters in LEED-Certified Building

Growing USME team supporting rising number of hospitals nationwide as the company recommits to Houston…

1 hour ago

KindlyMD Announces Second Quarter 2024 Financial Results and Provides Shareholder Update

Company provides nearly 80% statewide comprehensive insurance coverage in Utah under contract with providers such…

1 hour ago